Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: A phase I/II clinical trial

• DOI: 10.1073/pnas.96.13.7462
• Publication Date: 2002-07-26T14:41:48Z
• Authors: Robert B. Nussenb...; Eric Fortin; Rhett Schiffman; Luiz Rizzo; Janine Smith; Paul Van Veldhuisen; Pushpa Sran; Anita Yaffe; Carolyn K. Goldman; Thomas A. Waldmann; Scott M. Whitcup
• Keywords: Daclizumab; Clinical endpoint; Ciclosporin

To evaluate the safety and potential therapeutic activity of humanized anti-IL-2 receptor mAb (Daclizumab) therapy in treatment patients with severe, sight-threatening, intermediate posterior noninfectious uveitis, a nonrandomized, open-label, pilot study was performed. Patients uveitis were treated minimum 20 mg prednisone, cyclosporine, antimetabolites, or any combination these agents eligible. weaned off their systemic immunosuppressive according to standardized schedule, while ultimately receiving Daclizumab infusions every 4 weeks. Anti-IL-2 antibody therapy, given intravenously intervals up weeks lieu standard appeared prevent expression severe sight-threatening intraocular inflammatory disease 8 10 over 12-month period, noted improvements visual acuity. One patient met primary endpoint loss vision letters more from baseline one eye another discontinued because evidence increased ocular inflammation. All able tolerate medications without need for dose reduction. We report effective long-term use an autoimmune indication. These initial findings would suggest that may be approach and, by implication, other disorders predominant Th1 profile.